BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 19594771)

  • 1. Metabolic syndrome and cardiovascular risk in renal transplant recipients: effects of statin treatment.
    Soveri I; Abedini S; Holdaas H; Jardine A; Eriksson N; Fellström B
    Clin Transplant; 2009; 23(6):914-20. PubMed ID: 19594771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Graft loss risk in renal transplant recipients with metabolic syndrome: subgroup analyses of the ALERT trial.
    Soveri I; Abedini S; Holdaas H; Jardine A; Eriksson N; Fellström B
    J Nephrol; 2012; 25(2):245-54. PubMed ID: 21725919
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renal transplant dysfunction--importance quantified in comparison with traditional risk factors for cardiovascular disease and mortality.
    Soveri I; Holdaas H; Jardine A; Gimpelewicz C; Staffler B; Fellström B
    Nephrol Dial Transplant; 2006 Aug; 21(8):2282-9. PubMed ID: 16574686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular risk and renal transplantation: post hoc analyses of the Assessment of Lescol in Renal Transplantation (ALERT) Study.
    Jardine AG; Fellström B; Logan JO; Cole E; Nyberg G; Grönhagen-Riska C; Madsen S; Neumayer HH; Maes B; Ambühl P; Olsson AG; Pedersen T; Holdaas H
    Am J Kidney Dis; 2005 Sep; 46(3):529-36. PubMed ID: 16129216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beneficial effect of early initiation of lipid-lowering therapy following renal transplantation.
    Holdaas H; Fellström B; Jardine AG; Nyberg G; Grönhagen-Riska C; Madsen S; Neumayer HH; Cole E; Maes B; Ambühl P; Logan JO; Staffler B; Gimpelewicz C;
    Nephrol Dial Transplant; 2005 May; 20(5):974-80. PubMed ID: 15784644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. No detrimental effect on renal function during long-term use of fluvastatin in renal transplant recipients in the Assessment of Lescol in Renal Transplantation (ALERT) study.
    Fellström B; Abedini S; Holdaas H; Jardine AG; Staffler B; Gimpelewicz C;
    Clin Transplant; 2006; 20(6):732-9. PubMed ID: 17100723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk reduction and tolerability of fluvastatin in patients with the metabolic syndrome: a pooled analysis of thirty clinical trials.
    Winkler K; Ablethauser CB; Gimpelewicz C; Bortolini M; Isaacsohn JL
    Clin Ther; 2007 Sep; 29(9):1987-2000. PubMed ID: 18035198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic syndrome and cardiovascular disease in kidney transplantation.
    Salerno MP; Piselli P; Rossi E; Favi E; Gargiulo A; Spagnoletti G; Agresta A; Citterio F
    Transplant Proc; 2011 May; 43(4):1067-8. PubMed ID: 21620054
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fluvastatin reduces the impact of diabetes on long-term outcome after coronary intervention--a Lescol Intervention Prevention Study (LIPS) substudy.
    Arampatzis CA; Goedhart D; Serruys PW; Saia F; Lemos PA; de Feyter P;
    Am Heart J; 2005 Feb; 149(2):329-35. PubMed ID: 15846273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of fluvastatin on cardiac outcomes in kidney transplant patients with systemic lupus erythematosus: a randomized placebo-controlled study.
    Norby GE; Holme I; Fellström B; Jardine A; Cole E; Abedini S; Holdaas H;
    Arthritis Rheum; 2009 Apr; 60(4):1060-4. PubMed ID: 19333947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bisoprolol and fluvastatin for the reduction of perioperative cardiac mortality and myocardial infarction in intermediate-risk patients undergoing noncardiovascular surgery: a randomized controlled trial (DECREASE-IV).
    Dunkelgrun M; Boersma E; Schouten O; Koopman-van Gemert AW; van Poorten F; Bax JJ; Thomson IR; Poldermans D;
    Ann Surg; 2009 Jun; 249(6):921-6. PubMed ID: 19474688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of high-dose statin administered prior to coronary angioplasty on the incidence of cardiac events in patients with acute coronary syndrome.
    Chyrchel M; Rakowski T; Rzeszutko L; Legutko J; Dziewierz A; Dubiel JS; Dudek D
    Kardiol Pol; 2006 Dec; 64(12):1357-62; discussion 1363. PubMed ID: 17206539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of folic acid when added to statin therapy in patients with hypercholesterolemia following acute myocardial infarction: a randomised pilot trial.
    Liem AH; van Boven AJ; Veeger NJ; Withagen AJ; Robles de Medina RM; Tijssen JG; van Veldhuisen DJ;
    Int J Cardiol; 2004 Feb; 93(2-3):175-9. PubMed ID: 14975544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discordance between insulin resistance and metabolic syndrome: features and associated cardiovascular risk in adults with normal glucose regulation.
    Onat A; Hergenç G; Türkmen S; Yazici M; Sari I; Can G
    Metabolism; 2006 Apr; 55(4):445-52. PubMed ID: 16546474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of intensive statin therapy on clinical outcomes among patients undergoing percutaneous coronary intervention for acute coronary syndrome. PCI-PROVE IT: A PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) Substudy.
    Gibson CM; Pride YB; Hochberg CP; Sloan S; Sabatine MS; Cannon CP;
    J Am Coll Cardiol; 2009 Dec; 54(24):2290-5. PubMed ID: 19958964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term fluvastatin reduces the hazardous effect of renal impairment on four-year atherosclerotic outcomes (a LIPS substudy).
    Lemos PA; Serruys PW; de Feyter P; Mercado NF; Goedhart D; Saia F; Arampatzis CA; Soares PR; Ciccone M; Arquati M; Cortellaro M; Rutsch W; Legrand V
    Am J Cardiol; 2005 Feb; 95(4):445-51. PubMed ID: 15695126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differences between statins on clinical endpoints: a population-based cohort study.
    Dieleman JP; van Wyk JT; van Wijk MA; van Herpen G; Straus SM; Dunselman H; Sturkenboom MC
    Curr Med Res Opin; 2005 Sep; 21(9):1461-8. PubMed ID: 16197665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of the metabolic syndrome as influenced by the measure of obesity employed.
    Vega GL; Barlow CE; Grundy SM
    Am J Cardiol; 2010 May; 105(9):1306-12. PubMed ID: 20403484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic syndrome does not increase angiographic restenosis rates after drug-eluting stent implantation.
    Canibus P; Faloia E; Piva T; Muçai A; Serenelli M; Perna GP; Boscaro M; Piva R
    Metabolism; 2008 May; 57(5):593-7. PubMed ID: 18442619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic syndrome after kidney transplantation.
    Faenza A; Fuga G; Nardo B; Donati G; Cianciolo G; Scolari MP; Stefoni S
    Transplant Proc; 2007; 39(6):1843-6. PubMed ID: 17692629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.